SCHEMBL12377890

SCHEMBL12377890

CCc1ccc(C#N)nc1Cl

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.35
MAPT P10636 2/20 0.35
POLB P06746 1/20 0.35
NQO1 P15559 1/20 0.35
HTT P42858 2/20 0.33
CTRC Q99895 1/20 0.33
SOS2 Q07890 1/20 0.33
GLA P06280 1/20 0.33
GABRA1 P14867 1/20 0.32
GABRB2 P47870 1/20 0.32
CYP2A6 P11509 1/20 0.32
TKT P29401 1/20 0.32
KDM1A O60341 4/20 0.32
KDM4E B2RXH2 1/20 0.32
PTGS2 P35354 1/20 0.31
EGLN2 Q96KS0 1/20 0.31
P2RX3 P56373 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2290878 0.81 SOS2 (0.33) NQO1SOS2
SCHEMBL9087154 0.78 EGLN2 (0.37) ALDH1A1NQO1SOS2CYP2A6TKT
SCHEMBL27796512 0.78 SOS2 (0.32) NQO1SOS2TKT
SCHEMBL20599383 0.74 HSP90AB1 (0.38) ALDH1A1MAPTPOLBNQO1SOS2
SCHEMBL2291603 0.74 ALDH1A1 (0.44) ALDH1A1NQO1HTTSOS2GLA
SCHEMBL26136944 0.73 SOS2 (0.34) NQO1SOS2TKT
SCHEMBL5745630 0.73 CTRC (0.39) MAPTCTRCGABRA1GABRB2TKT
SCHEMBL7846050 0.73 SOS2 (0.38) ALDH1A1POLBNQO1SOS2KDM4E
SCHEMBL9181886 0.71 CTRC (0.38) ALDH1A1POLBCTRCKDM4EKMT2A
SCHEMBL20602014 0.70 PDE2A (0.33) NQO1SOS2EGLN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250129-A1 NEUROACTIVE STEROIDS AND COMPOSITIONS THEREOF SAGE THERAPEUTICS, INC. 2023-08-10 US disclosed
WO-2021262836-A1 3.ALPHA.-HYDROXY, 17.BETA.-C(O)-N-ARYL SUBSTITUTED NEUROACTIVE STEROIDS AND COMPOSITIONS THEREOF SAGE THERAPEUTICS, INC. (US) 2021-12-30 WO disclosed
US-7998954-B2 Pyrimidodiazepinone derivative KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-08-16 US disclosed
US-7998954-B2 Pyrimidodiazepinone derivative KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-08-16 US disclosed
US-20100190775-A1 PYRIMIDODIAZEPINONE DERIVATIVE KYOWA HAKKO KIRIN CO., LTD (JP) 2010-07-29 US disclosed
US-20100190775-A1 PYRIMIDODIAZEPINONE DERIVATIVE KYOWA HAKKO KIRIN CO., LTD (JP) 2010-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250129-A1 NEUROACTIVE STEROIDS AND COMPOSITIONS THEREOF MC2R, NR3C2, AVPR1B ALDH1A1 1664/4885MAPT 717/4885POLB 4325/4885
US-20100190775-A1 PYRIMIDODIAZEPINONE DERIVATIVE KCNJ1, KCNJ11, ADRA1D ALDH1A1 407/4885MAPT 4573/4885POLB 1331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.